Latest On Amphastar Pharmaceuticals, Inc (AMPH):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-14 02:15 EST | News | Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-09 23:58 EST | News | Amphastar Pharmaceuticals Non-GAAP EPS of $0.62 beats by $0.13, revenue of $140M beats by $4.37M | N/A | |
| 2023-05-08 20:58 EST | News | Amphastar Pharmaceuticals Q1 2023 Earnings Preview | N/A | |
| 2023-05-08 07:44 EST | News | Amphastar Pharmaceuticals (AMPH) Presents At 22nd Annual Needham Virtual Healthcare Conference - Slideshow | N/A | |
| 2023-04-24 15:29 EST | News | Eli Lilly to divest diabetes therapy Baqsimi to Amphastar | N/A | |
About Amphastar Pharmaceuticals, Inc (AMPH):
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse othe read more...r injected drugs; lidocaine jelly, a local anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection for newborn babies; atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; morphine injection; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as recombinant human insulin API (active pharmaceutical ingredients) and porcine insulin API. Further, the company has a pipeline of 20 product candidates in various stages of development for various indications. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
General
- Name Amphastar Pharmaceuticals, Inc
- Symbol AMPH
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 1,980
- Fiscal Year EndDecember
- IPO Date2014-06-25
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.amphastar.com
Valuation
- Trailing PE 597
- Price/Sales (Trailing 12 Mt.) 2.53
- Price/Book (Most Recent Quarter) 2.12
- Enterprise Value Revenue 2.33
- Enterprise Value EBITDA 26.99
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $0.94
- Next Year EPS Estimate $1.37
- Next Quarter EPS Estimate $0.18
- Profit Margin 0%
- Operating Margin 5%
- Return on Assets 2%
- Revenue 349.85 million
- Earnings Per Share $0.03
- Revenue Per Share $7.44
- Gross Profit 143.34 million
- Quarterly Earnings Growth 15%
Highlights
- Market Capitalization 849.52 million
- EBITDA 37.38 million
- PE Ratio 14.25
- PEG Ratio 2.77
- Analyst Target Price $21.2
- Book Value Per Share $8.47
Share Statistics
- Shares Outstanding 47.43 million
- Shares Float 36.55 million
- % Held by Insiders 2337%
- % Held by Institutions 56.05%
- Shares Short 2.57 million
- Shares Short Prior Month 2.55 million
- Short Ratio 15.87
- Short % of Float 8%
- Short % of Shares Outstanding 5%
Technicals
- Beta 0.8
- 52 Week High $22.69
- 52 Week Low $12.66
- 50 Day Moving Average 18.41
- 200 Day Moving Average 19.15
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Amphastar Pharmaceuticals, Inc (AMPH) Dividend Calendar:
Amphastar Pharmaceuticals, Inc (AMPH) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Amphastar Pharmaceuticals, Inc (AMPH) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Amphastar Pharmaceuticals, Inc (AMPH) Chart:
Amphastar Pharmaceuticals, Inc (AMPH) News:
Below you will find a list of latest news for Amphastar Pharmaceuticals, Inc (AMPH) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Amphastar Pharmaceuticals, Inc (AMPH) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest AMPH Trades:
Amphastar Pharmaceuticals, Inc (AMPH) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-06 | 8-K (Current report) | |
| 2020-11-06 | 8-K (Current report) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-10 | 8-K/A (Current report) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-10 | 4 (Statement of changes in beneficial ownership of securities) | |
Amphastar Pharmaceuticals, Inc (AMPH) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Amphastar Pharmaceuticals, Inc (AMPH). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2337%
Institutional Ownership: 5605%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-02 | Floyd F. Petersen | Director | Sell | 500.00 | 19.84 | 9,919.95 | 74,493.00 | |
| 2020-10-01 | Floyd F. Petersen | Director | Sell | 500.00 | 18.89 | 9,445.80 | 74,993.00 | |
| 2020-09-01 | Floyd F. Petersen | Director | Sell | 500.00 | 19.90 | 9,948.05 | 75,493.00 | |
| 2020-08-14 | David Maris | Director | Buy | 1,000.00 | 20.26 | 20,260.00 | 13,151.00 | |
| 2020-08-14 | WILLIAM J PETERS | CFO, SVP & Treasurer | Sell | 5,512.00 | 20.36 | 112,223.22 | 95,652.00 | |
| 2020-08-11 | RICHARD K PRINS | Director | Sell | 6,000.00 | 20.33 | 121,976.40 | 39,160.00 | |
| 2020-08-03 | Floyd F. Petersen | Director | Sell | 500.00 | 20.62 | 10,307.75 | 75,993.00 | |
| 2020-07-21 | Yakob Liawatidewi | EVP Corp Admin Center | Sell | 5,978.00 | 21.22 | 126,837.02 | 45,996.00 | |
| 2020-07-21 | Yakob Liawatidewi | EVP Corp Admin Center | Buy | 5,978.00 | 11.33 | 67,730.74 | 51,974.00 | |
| 2020-07-20 | Yakob Liawatidewi | EVP Corp Admin Center | Sell | 4,186.00 | 21.03 | 88,046.65 | 45,996.00 | |
| 2020-07-20 | Yakob Liawatidewi | EVP Corp Admin Center | Buy | 4,186.00 | 11.33 | 47,427.38 | 50,182.00 | |
| 2020-07-06 | WILLIAM J PETERS | CFO, SVP & Treasurer | Sell | 13,656.00 | 22.00 | 300,404.69 | 101,164.00 | |
| 2020-07-06 | WILLIAM J PETERS | CFO, SVP & Treasurer | Buy | 10,000.00 | 11.33 | 113,300.00 | 114,820.00 | |
| 2020-07-01 | Floyd F. Petersen | Director | Sell | 500.00 | 22.27 | 11,135.60 | 76,493.00 | |
| 2020-06-09 | Yakob Liawatidewi | EVP Corp Admin Center | Sell | 23,405.00 | 20.41 | 477,602.43 | 46,124.00 | |
| 2020-06-09 | Yakob Liawatidewi | EVP Corp Admin Center | Buy | 16,000.00 | 10.93 | 174,880.00 | 69,529.00 | |
| 2020-06-08 | David Maris | Director | Buy | 5,851.00 | 12,151.00 | | ||
| 2020-06-08 | Howard Lee | Director | Buy | 5,851.00 | 133,269.00 | | ||
| 2020-06-08 | Richard Koo | Director | Buy | 5,851.00 | 253,270.00 | | ||
| 2020-06-08 | MICHAEL A ZASLOFF | Director | Buy | 5,851.00 | 41,187.00 | |